'Thriving With Bipolar Disorder': Co-design and Evaluation of a Peer-Led Education Program Focused on Quality of Life
Opening soon NCT06878937
Run by University of British Columbia · for 18 and older · All sexes
What this study is about
Self-management strategies can be used by individuals with bipolar disorder (BD) to cope with symptoms and improve quality of life (QoL). Peer-facilitated education programs have the potential to diversify delivery of self-management information by capitalizing on the expertise of individuals who live well with BD. We have co-designed a novel, peer-facilitated, QoL-focused, group education program for people living with BD. This project will involve administration of the program and an evaluation of the feasibility, acceptability, and efficacy of this program for self-management of BD.
Who can join (things the study team will check)
✅ You may be able to join if…
- Program facilitators
- aged 18 or older
- a self-reported diagnosis of a mood disorder
- sufficient access to an internet-enabled computer or smartphone device to access the Zoom teleconferencing platform
- ability to understand, read and write English
- at least one year of prior experience leading peer support groups or recovery programs through Hope+Me
- previously received training through Hope+Me
- completed a Criminal Records Check
- Program participants
- aged 18 or older
- residing in Canada
- a self-reported diagnosis of BD
- ability to understand, read and write English
- sufficient access to an internet-enabled computer or smartphone device to access the Zoom teleconferencing platform
🚫 You may not be able to join if…
- inability to communicate in written and verbal English to a sufficient level to allow participation in the program and research activities
Where this trial is running
- University of British Columbia, Vancouver, British Columbia, Canada
Who to contact
Erin Michalak · 604-827-3393 · erin.michalak@ubc.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06878937.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.